Börsipäev 23 - 24. mai

LHV Pro all ka mõned uued huvitavad analüüsid.
Järgmine General Motorsi (GM) võla daungreid täna, sedapuhku siis Fitch langetab junki peale.
LHV Pro all veidi uuendatud RedEnvelope (REDE) teemat. CEO ostis täna hommikul aktsiaid ning lisaks sellele pikemalt juttu ka ühest huvitavast kaasaktsionärist.

sB
Eyetech Announces Conference Call to Reiterate Confidence in Macugen(R)
(Pegaptanib Sodium Injection)

NEW YORK, May 24 /PRNewswire-FirstCall/ -- Eyetech Pharmaceuticals, Inc.
(Nasdaq: EYET) announced that it will hold a conference call to reiterate its
confidence in Macugen and discuss issues presented by a potential competitor's
recently released preliminary, top-line clinical trial data for the potential
use of an antibody fragment in the treatment of neovascular age-related
macular degeneration (neovascular AMD). Neovascular AMD is the leading cause
of blindness in people over 60 years of age.
(Logo: http://www.newscom.com/cgi-bin/prnh/20050407/EYETLOGO )
Conference Call and Webcast Information
Eyetech will hold the conference call and simultaneous webcast on
Thursday, May 26, 2005, at 8:30 a.m., Eastern Time. Live audio of the
conference call will be available to investors, members of the news media and
the general public by dialing 888-275-0218 (in the United States) or
706-679-7756 (internationally).
EYET eelturul juba 14.07 ehk +8.65% eilsega võrreldes.